Aldeyra Therapeutics, Inc. (ALDX)
ALDXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.6893
+0.1089 (+18.76%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $38.39m
- P/E
- –
- EPS, last 4 quarters
- $-0.3900
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.5271 to $5.93
- Average volume
- 1.25m
- Previous close
- $0.5804
Analysts
1 coveringBuy0 buy, 1 hold, 0 sell
Targets a year out average $2.00, +190.1% from here
Earnings
next estimate $-0.1100Next report Nov 11, 2026
Sep 2025
+23.5%
Dec 2025
+21.4%
Mar 2026
+53.9%
Jun 2026
+18.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$8.00m | -$6.67m | -$3.55m | -$5.85m |
| Net income | -$7.69m | -$6.46m | -$3.45m | -$5.45m |
News
8 latest- Aldeyra Therapeutics, Inc. Requests FDA Review Jurisdiction Transfer for ADX-2191Fintel · 3 hours ago
- RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekZacks · Oct 15, 2026
- Here's Why You Should Add ANRO Stock to Your Portfolio NowZacks · Oct 14, 2026
- Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalZacks · Oct 14, 2026
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyZacks · Oct 12, 2026
- PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowZacks · Oct 12, 2026
- argenx Meets Primary Endpoint in Phase II Celiac Disease StudyZacks · Oct 9, 2026
- EDIT Set to Begin First-in-Human Study in Hypercholesterolemia Zacks · Oct 9, 2026
The company
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248 and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- aldeyra.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.